MedTrace Logo

Systane Ultra Versus Maxidex Versus Saline

NCT01775540 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-01-25

No results posted yet for this study

Summary

This study was to evaluate the healing action on the eye surface of the artificial tear Systane® ULTRA as compared to two other eyedrops: Maxidex and Saline solution. Dry eye disease leads to inflammation of the eye surface and treating dry eyes with artificial tears may lead to reduction in this inflammation and improvement of symptoms and signs.

Conditions

Interventions

DRUG

Systane Ultra

Artificial tear Eyedrop, 1 drop used QID for 4 weeks

DRUG

Saline solution

Saline solution,1 drop used QID for 4 weeks

DRUG

Maxidex

Eyedrop-1 drop QID for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Penny Asbell, MD, MBA, FACS · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01775540 on ClinicalTrials.gov